New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
04:55 EDTLIFE, LIFE, LIFE, SI, SI, SI, BIOL, BIOL, BIOL, IVC, IVC, IVC, VAR, VAR, VAR, ARAY, ARAY, ARAY, CPHD, CPHD, CPHD, MASI, MASI, MASI, HRC, HRC, HRC, RHHBY, RHHBY, RHHBY, MCK, MCK, MCKWorldwide Business Research to host a conference
Field Service Medical Conference is being held in San Diego on February 19-21.
News For LIFE;RHHBY;HRC;MASI;CPHD;ARAY;VAR;IVC;BIOL;SI;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
October 17, 2014
10:00 EDTMCKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
October 16, 2014
17:35 EDTCPHDCepheid 'well positioned' to address Ebola
Subscribe for More Information
17:28 EDTCPHDCepheid sees Q4 adjusted EPS 2c-4c, may not compare to consensus (9c)
Subscribe for More Information
16:20 EDTMCKMcKesson initiated with an Outperform at RBC Capital
Subscribe for More Information
16:11 EDTCPHDCepheid sees FY14 adjusted EPS 11c-13c, may not compare to consensus (52c)
Subscribe for More Information
16:09 EDTCPHDCepheid reports Q3 EPS ex-items 6c, consensus (16c)
Subscribe for More Information
14:47 EDTRHHBYRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:13 EDTRHHBYRoche considers submitting Ebola test for emergency use approval, WSJ says
Subscribe for More Information
09:35 EDTRHHBYDiplomat announces contract to distribute Esbriet
Subscribe for More Information
08:17 EDTMASIMasimo announces two new clinical studies of SpHb
Subscribe for More Information
05:58 EDTRHHBYRoche sees FY14 core EPS targeted to grow ahead of sales
Subscribe for More Information
05:56 EDTRHHBYRoche reports 9 month revenue CHF34.76B vs. CHF34.87B last year
Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”
October 15, 2014
17:09 EDTMASIMasimo study shows benefit of Oxygen Reserve Index
Subscribe for More Information
15:45 EDTRHHBYFDA approves Esbriet to treat idiopathic pulmonary fibrosis
Subscribe for More Information
October 14, 2014
11:23 EDTRHHBYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
08:16 EDTMASIMasimo announced positive results of retrospective study of ERAS program
Subscribe for More Information
07:48 EDTCPHDCepheid recent weakness unjustified, says Canaccord
Subscribe for More Information
October 13, 2014
07:37 EDTMASI, MCKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use